Silo Pharma Inc（SILO）财务数据SILOSilo Pharma Inc

Evaluating the bottom line, Silo Pharma Inc maintains a gross margin of -14.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8846.44%, while the net margin is -9137.45%. These profitability ratios, combined with a Return on Equity (ROE) of -99.94%, provide a clear picture of how effectively SILO converts its operational activities into shareholder value.

In the context of the broader market, SILO competes directly with industry leaders such as RDHL and MBIO. With a market capitalization of $5.08M, it holds a leading position in the sector. When comparing efficiency, SILO's gross margin of -14.77% stands against RDHL's 100.00% and MBIO's N/A. Such benchmarking helps identify whether Silo Pharma Inc is trading at a premium or discount relative to its financial performance.

Silo Pharma has reported consistent negative net income, with the latest quarter showing a net income of -1,647,117 USD and a gross margin that has turned negative at -14.77% in recent quarters, suggesting deteriorating financial health.